Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer.

W J Urba(Frederick National Laboratory for Cancer Research), Jeffrey W. Clark(Massachusetts General Hospital), Ronald G. Steis, William C. Kopp(Frederick National Laboratory for Cancer Research), A E Maluish, Luisa Marcon, Dan L. Longo(Harvard University), H C Stevenson(University of Virginia), David L. Nelson(Smithsonian Conservation Biology Institute)
PubMed
January 1, 1990
Cited by 60

Related Papers

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome
|Cell|1991|3.5k
Variation of the CGG repeat at the fragile X site results in genetic instability: Resolution of the Sherman paradox
|Cell|1991|2.1k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k